Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles

Tsutomu Ishihara, Miyuki Takahashi, Megumu Higaki, Mitsuko Takenaga, Tohru Mizushima, Yutaka Mizushima

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose. Prostaglandins have potent and diverse biologic activities, but their clinical application is severely restricted, mainly due to rapid inactivation in vivo. In order to modulate the pharmacokinetics of prostaglandin E1 (PGE1), we prepared biodegradable nanoparticles as a drug carrier. Methods. Nanoparticles encapsulating PGE1 were prepared from a blend of poly(lactic acid) homopolymer and poly(ethylene glycol)-poly(lactide) block copolymer by the solvent diffusion method in the presence of iron. Results. PGE1 was efficiently and stably embedded in the nanoparticles through interaction with iron, despite being relatively hydrophilic and having unstable chemical properties. Depending on the isomers and molecular weight of poly(lactic acid) selected, PGE1 was gradually released from the nanoparticles at various rates into diluted serum in vitro. Both stable retention of PGE1 in the nanoparticles and coating of the nanoparticles with poly(ethylene glycol) led to an extremely extended blood residence time of PGE1, as well as preferential accumulation in vascular lesions. Conclusions. These results suggest that the present strategy is useful to advance the clinical application of PGE 1 as a therapeutic agent for vascular disorders.

Original languageEnglish
Pages (from-to)1686-1695
Number of pages10
JournalPharmaceutical Research
Volume25
Issue number7
DOIs
Publication statusPublished - 2008 Jul
Externally publishedYes

Fingerprint

Alprostadil
Nanoparticles
Ethylene Glycol
Polyethylene glycols
Blood Vessels
Iron
Drug Carriers
Pharmacokinetics
Prostaglandins E
Homopolymerization
Isomers
Chemical properties
Block copolymers
Prostaglandins
Blood
Molecular Weight
Molecular weight
Coatings
Serum

Keywords

  • Iron
  • Nanoparticle
  • Poly(lactic acid)
  • Prostaglandin E
  • Vascular disorder

ASJC Scopus subject areas

  • Chemistry(all)
  • Pharmaceutical Science
  • Pharmacology

Cite this

Ishihara, T., Takahashi, M., Higaki, M., Takenaga, M., Mizushima, T., & Mizushima, Y. (2008). Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles. Pharmaceutical Research, 25(7), 1686-1695. https://doi.org/10.1007/s11095-008-9549-8

Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles. / Ishihara, Tsutomu; Takahashi, Miyuki; Higaki, Megumu; Takenaga, Mitsuko; Mizushima, Tohru; Mizushima, Yutaka.

In: Pharmaceutical Research, Vol. 25, No. 7, 07.2008, p. 1686-1695.

Research output: Contribution to journalArticle

Ishihara, T, Takahashi, M, Higaki, M, Takenaga, M, Mizushima, T & Mizushima, Y 2008, 'Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles', Pharmaceutical Research, vol. 25, no. 7, pp. 1686-1695. https://doi.org/10.1007/s11095-008-9549-8
Ishihara T, Takahashi M, Higaki M, Takenaga M, Mizushima T, Mizushima Y. Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles. Pharmaceutical Research. 2008 Jul;25(7):1686-1695. https://doi.org/10.1007/s11095-008-9549-8
Ishihara, Tsutomu ; Takahashi, Miyuki ; Higaki, Megumu ; Takenaga, Mitsuko ; Mizushima, Tohru ; Mizushima, Yutaka. / Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles. In: Pharmaceutical Research. 2008 ; Vol. 25, No. 7. pp. 1686-1695.
@article{4bf22132215c464383f90c848f9412f6,
title = "Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles",
abstract = "Purpose. Prostaglandins have potent and diverse biologic activities, but their clinical application is severely restricted, mainly due to rapid inactivation in vivo. In order to modulate the pharmacokinetics of prostaglandin E1 (PGE1), we prepared biodegradable nanoparticles as a drug carrier. Methods. Nanoparticles encapsulating PGE1 were prepared from a blend of poly(lactic acid) homopolymer and poly(ethylene glycol)-poly(lactide) block copolymer by the solvent diffusion method in the presence of iron. Results. PGE1 was efficiently and stably embedded in the nanoparticles through interaction with iron, despite being relatively hydrophilic and having unstable chemical properties. Depending on the isomers and molecular weight of poly(lactic acid) selected, PGE1 was gradually released from the nanoparticles at various rates into diluted serum in vitro. Both stable retention of PGE1 in the nanoparticles and coating of the nanoparticles with poly(ethylene glycol) led to an extremely extended blood residence time of PGE1, as well as preferential accumulation in vascular lesions. Conclusions. These results suggest that the present strategy is useful to advance the clinical application of PGE 1 as a therapeutic agent for vascular disorders.",
keywords = "Iron, Nanoparticle, Poly(lactic acid), Prostaglandin E, Vascular disorder",
author = "Tsutomu Ishihara and Miyuki Takahashi and Megumu Higaki and Mitsuko Takenaga and Tohru Mizushima and Yutaka Mizushima",
year = "2008",
month = "7",
doi = "10.1007/s11095-008-9549-8",
language = "English",
volume = "25",
pages = "1686--1695",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles

AU - Ishihara, Tsutomu

AU - Takahashi, Miyuki

AU - Higaki, Megumu

AU - Takenaga, Mitsuko

AU - Mizushima, Tohru

AU - Mizushima, Yutaka

PY - 2008/7

Y1 - 2008/7

N2 - Purpose. Prostaglandins have potent and diverse biologic activities, but their clinical application is severely restricted, mainly due to rapid inactivation in vivo. In order to modulate the pharmacokinetics of prostaglandin E1 (PGE1), we prepared biodegradable nanoparticles as a drug carrier. Methods. Nanoparticles encapsulating PGE1 were prepared from a blend of poly(lactic acid) homopolymer and poly(ethylene glycol)-poly(lactide) block copolymer by the solvent diffusion method in the presence of iron. Results. PGE1 was efficiently and stably embedded in the nanoparticles through interaction with iron, despite being relatively hydrophilic and having unstable chemical properties. Depending on the isomers and molecular weight of poly(lactic acid) selected, PGE1 was gradually released from the nanoparticles at various rates into diluted serum in vitro. Both stable retention of PGE1 in the nanoparticles and coating of the nanoparticles with poly(ethylene glycol) led to an extremely extended blood residence time of PGE1, as well as preferential accumulation in vascular lesions. Conclusions. These results suggest that the present strategy is useful to advance the clinical application of PGE 1 as a therapeutic agent for vascular disorders.

AB - Purpose. Prostaglandins have potent and diverse biologic activities, but their clinical application is severely restricted, mainly due to rapid inactivation in vivo. In order to modulate the pharmacokinetics of prostaglandin E1 (PGE1), we prepared biodegradable nanoparticles as a drug carrier. Methods. Nanoparticles encapsulating PGE1 were prepared from a blend of poly(lactic acid) homopolymer and poly(ethylene glycol)-poly(lactide) block copolymer by the solvent diffusion method in the presence of iron. Results. PGE1 was efficiently and stably embedded in the nanoparticles through interaction with iron, despite being relatively hydrophilic and having unstable chemical properties. Depending on the isomers and molecular weight of poly(lactic acid) selected, PGE1 was gradually released from the nanoparticles at various rates into diluted serum in vitro. Both stable retention of PGE1 in the nanoparticles and coating of the nanoparticles with poly(ethylene glycol) led to an extremely extended blood residence time of PGE1, as well as preferential accumulation in vascular lesions. Conclusions. These results suggest that the present strategy is useful to advance the clinical application of PGE 1 as a therapeutic agent for vascular disorders.

KW - Iron

KW - Nanoparticle

KW - Poly(lactic acid)

KW - Prostaglandin E

KW - Vascular disorder

UR - http://www.scopus.com/inward/record.url?scp=44749083638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44749083638&partnerID=8YFLogxK

U2 - 10.1007/s11095-008-9549-8

DO - 10.1007/s11095-008-9549-8

M3 - Article

C2 - 18293063

AN - SCOPUS:44749083638

VL - 25

SP - 1686

EP - 1695

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 7

ER -